CagriSema at a glance
| Detail | What the sources say |
|---|---|
| Developer | Novo Nordisk |
| What it is | Cagrilintide (amylin analogue) combined with semaglutide (GLP-1 receptor agonist) |
| Stage | Phase 3 (REDEFINE); submitted to the FDA on 18 December 2025 |
| Approved? | No, as of the update date |
| Published evidence | REDEFINE 1, NEJM 2025 |
From the sources to the app
| What the sources say | What PepLabo does with it |
|---|---|
| No approved label exists, so there is no official schedule or storage rule. | PepLabo fills in nothing; amounts, schedules and dates come from you or your study team. |
| CagriSema is a fixed combination of two substances [3]. | The library lists it as a combination, and it stays a separate product from plain semaglutide in your history. |
| The phase 3 REDEFINE programme is registered on ClinicalTrials.gov [2]. | The library entry shows the current status with sources and dates. |
What PepLabo does and does not do
| PepLabo does | PepLabo does not |
|---|---|
| Record each dose with the date, time and amount you enter, and the site for injections | Suggest a dose, a schedule change or a medicine |
| Remind you 15 minutes before, at the dose time, and 30 minutes after a missed dose | Tell you what to do after a missed dose; the leaflet and your prescriber do |
| Put check-ins, weight and doses on one timeline | Interpret symptoms or judge progress |
| Keep your records on your phone, with no account needed to track | Use analytics, advertising or tracking SDKs, or write to Apple Health |
| Create a PDF of your dose log for your clinician (Pro) | Replace your clinician or pharmacist |
